Dubai Future Accelerators to Pick New Cohort of Innovative Startups to Address Global Challenges
17.11.2019 20:39:00 EET | Business Wire | Press release
Dubai Future Accelerators (DFA), an initiative of Dubai Future Foundation (DFF) and the Government of Dubai, is once again scouting new talent from among the world’s most innovative startups and scale-ups to join its flagship program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191117005057/en/
Dubai Future Accelerators convened participants to brainstorm innovative solutions at Cohort 6 (Photo: AETOSWire)
DFA is set up as a business development and market-entry accelerator based on specific demands identified by its partners. Startups and scale-ups offering software or product-solutions that meet partners’ requirements are invited to submit their applications until November 30, 2019.
Cohort 7 will invite startups to experiment with emerging technologies, including artificial intelligence (AI) to brainstorm innovative solutions to the likely challenges facing cities of the future in key industries, such as healthcare, transportation, and safety and security.
With DFA facilitating collaborations, the companies will work hand in hand with government entities to address their industry-specific issues. Participating government partners will include Dubai Electricity and Water Authority (DEWA), the Roads and Transport Authority (RTA), the Dubai Health Authority (DHA), Dubai Police and Etisalat Digital.
The launch of this year’s edition follows the success of six earlier cohorts that synergized 13 government entities and 219 startups on 97 challenges. Furthermore, 71 percent of these startups have signed agreements with their partner entities to test their solutions through pilot projects or implement them within their organizations.
Dubai Future Accelerators is an intensive nine-week program that forges partnerships with government entities and private sector organizations from Dubai with startups, scale-ups and innovative SMEs from around the world to co-create transformational solutions. It offers a unique opportunity for entrepreneurs to use the city as a test bed for their avant-garde prototypes.
Companies selected to join our 7th cohort get invited to an in-residence program where participants will benefit from direct access to senior decision makers, access to a coworking space, paid roundtrip airfare to Dubai and paid accommodation for the duration of their participation in the mentorship program. Furthermore, DFA does not take any equity in the participating startups.
Interested startups that are keen to participate in the global challenge and shape solutions for the future can register now at https://dubaifutureaccelerators.com/en/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191117005057/en/
Contact information
Dubai Future Foundation
Noora Al Hathboor, +97145166522
noora.alhathboor@dubaifuture.gov.ae
http://www.dubaifuture.gov.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom